Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Autor: Ramasamy, Maheshi N1 (AUTHOR) maheshi.ramasamy@paediatrics.ox.ac.uk, Minassian, Angela M1,2 (AUTHOR), Ewer, Katie J1,2 (AUTHOR), Flaxman, Amy L1,2 (AUTHOR), Folegatti, Pedro M1,2 (AUTHOR), Owens, Daniel R1,3 (AUTHOR), Voysey, Merryn1 (AUTHOR), Aley, Parvinder K1 (AUTHOR), Angus, Brian2 (AUTHOR), Babbage, Gavin2 (AUTHOR), Belij-Rammerstorfer, Sandra2 (AUTHOR), Berry, Lisa3 (AUTHOR), Bibi, Sagida1 (AUTHOR), Bittaye, Mustapha2 (AUTHOR), Cathie, Katrina4 (AUTHOR), Chappell, Harry3 (AUTHOR), Charlton, Sue5 (AUTHOR), Cicconi, Paola2 (AUTHOR), Clutterbuck, Elizabeth A1,6 (AUTHOR), Colin-Jones, Rachel1 (AUTHOR)
Zdroj: Lancet. 12/19/2020, Vol. 396 Issue 10267, p1979-1993. 15p.
Databáze: Business Source Ultimate